Suh and PharmE3D Labs Win Fellowships for 3D Bioprinting Research

A woman smiling in front of a sign that says "Pharmacy."
March 18, 2021
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.

Has a UT Professor Found a Way to Stop COVID-19 Vaccines From Spoiling?

A fruit roll treat floating in the clouds with a rainbow behind it and small viruses hovering around it.
February 24, 2021
Molecular Pharmaceutics and Drug Delivery Professor Maria A. Croyle, Ph.D. received extensive coverage in the March 2021 edition of Texas Monthly regarding her innovative peelable film drug delivery research. Among its many potential applications, Dr. Croyle’s technology could deliver COVID-19 vaccines through a small oral strip, without need for refrigeration or extensive storage and transportation infrastructure.

Croyle Earns Funding for SARS-CoV-2 Research

A woman smiling.
January 13, 2021
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle R.Ph., Ph.D. earned 2021’s David Lehr Research Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Croyle will receive research funding to investigate novel regulatory mechanisms of drug metabolism in the context of active infection with SARS-CoV-2 and after recovery.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

New Thin Film Technology to Revolutionize Storage and Distribution of Biologic Treatments and Vaccines

A hand touching a transparent sheet.
September 29, 2020
The newly-formed Jurata Thin Film will work to bring Dr. Maria Croyle's thin film technology to market, allowing biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.

UT 3D Printing Labs Enter Patent License Agreement to Develop Digital 3D Drug Manufacturing and Advanced Drug Delivery Systems

Patient-centric 3D printing paradigm of medicines at the point-of-care.
July 17, 2020
Assistant Professor Mo Maniruzzaman’s Pharmaceutical Engineering and 3D Printing (PharmE3D) labs have entered an agreement with UK-based CoM3D to develop digital 3D drug manufacturing and advanced drug delivery systems.

Maniruzzaman Lab Collaboration Works to Develop Patient-Focused Medicines More Efficiently

mo lab 3d printer
April 27, 2020
To meet the need to develop methods to make drugs more soluble and usable, the Maniruzzaman Lab teamed up with Advanced Material Development (AMD) to address challenges with the reduction in quantity of new drugs coming to market.

3D-Printing Project Aims to Meet UT Community’s PPE Needs

face sheild visors in bulk
April 8, 2020
Mo Maniruzzaman‘s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab is 3D-printing face shields to meet PPE demands at UT health institutions during the COVID-19 pandemic.

Croyle Lab Develops Innovative Vaccine Delivery Method

maria croyle vaccine 2020
March 4, 2020
Researchers in the lab of Dr. Maria Croyle have developed a peelable lightweight film that stabilizes biologics, is inexpensive, and withstands extreme temperature changes. The technology has already demonstrated proof of concept for model Ebola and H1N1 vaccines, and may prove an effective method of delivery for future treatments, such as for coronavirus that causes COVID-19.